After norovirus vaccine's trial failure, HilleVax lays off 40% of staff
Boston biotech HilleVax said Wednesday that it will let go about 41 employees, or roughly 40% of its staff, after its lead vaccine failed a mid-stage test earlier in July. The Takeda spinout’s share...
View ArticleClik here to view.
Teladoc records $790M charge, withdraws outlook as mental health business...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Teladoc Health on Wednesday reported a steep loss in the second quarter, thanks to a $790 million...
View ArticleClik here to view.
Sage changes main endpoint in Huntington's study months ahead of readout
Sage Therapeutics is altering the primary endpoint of a Phase 2 study for its drug candidate dalzanemdor in cognitive impairment associated with Huntington’s disease, just months before trial results...
View ArticleOtsuka makes $800M acquisition of Jnana Therapeutics to expand small molecule...
Otsuka Pharmaceutical is paying at least $800 million to acquire Jnana Therapeutics, a Roche-partnered small molecule drug discovery outfit ready to put its first candidate into a pivotal trial next...
View ArticleEli Lilly’s Zepbound reduces risk of heart failure outcomes in Phase 3 study
Eli Lilly has declared victory in the first late-stage trial testing tirzepatide’s effect on cardiovascular outcomes, as it looks to catch up with Novo Nordisk and solidify its lead over newer entrants...
View ArticleRare disease biotech raises $47M Series C, plans for Phase 2 trial
Cambridge, UK-based Healx has pulled in $47 million in a Series C round and has nabbed IND clearance from the FDA to run its first Phase 2 clinical trial with an oral drug in neurofibromatosis type 1,...
View ArticleClik here to view.
It took more than two decades for MDMA to reach the FDA. In two months, its...
Lykos Therapeutics had planned to be the first company to bring PTSD patients a much-needed new treatment. Then in May, an influential outside group raised serious concerns about how its trial was run....
View ArticleUS sales for Merck KGaA’s Bavencio impacted by Padcev/Keytruda momentum in...
Following the standing ovation for Seagen and Astellas’ Padcev in combination with Merck’s Keytruda at last year’s ESMO Congress, Merck KGaA is seeing US sales erode for its urothelial carcinoma drug...
View ArticleJim Wilson to step down from gene therapy center at UPenn, will form two new...
Gene therapy pioneer Jim Wilson will leave his main academic post at the University of Pennsylvania and launch two new companies, one focused on developing rare diseases and another meant to provide...
View ArticleClik here to view.
VC firm venBio secures $528M for ‘extremely selective’ fifth fund after...
San Francisco-based investment firm venBio plans to back about a dozen new biotech startups over the coming three years with its latest fund, disclosed Thursday morning. Aaron Royston The firm...
View ArticleClik here to view.
AbbVie closes $8.7B Cerevel deal in bid to compete with Bristol Myers in...
AbbVie has received regulatory clearance to complete its $8.7 billion acquisition of neuroscience biotech Cerevel Therapeutics, the companies said Thursday. The move gives the Chicago-area pharma giant...
View ArticleWith $144M Series B, Outpace Bio beats funding goal for solid tumor cell...
Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B to gather clinical data from its first two...
View ArticleClik here to view.
Biogen CEO sees Alzheimer's drug on right path despite tiny sales, will keep...
A year after unveiling its “Fit for Growth” restructuring effort, Biogen is on track to reverse multiple years of declining revenues, CEO Chris Viehbacher told reporters Thursday. The Cambridge,...
View ArticleSanofi pours €1.3B into new insulin manufacturing plant in Frankfurt
Sanofi is investing €1.3 billion into a new insulin production facility in Germany to help with long-term supply and add power to its European supply chain. The 36,000 square-meter facility will be...
View ArticleArbutus reduces headcount after axing HBV combo trial that features Imfinzi
Arbutus plans to lay off 40% of its staff after ending one of three ongoing midstage hepatitis B trials. The decision to cut the study — testing lead asset imdusiran plus a nucleos(t)ide analogue in...
View ArticleBlueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset
Plus, news about Novo Holdings, Oxford Nanopore, Ionis, Valneva, LimmaTech and Bayer: Blueprint pulls in $114.1 million for Ayvakit: The company raised its net product revenue guidance to between $435...
View ArticlePfizer mulls facility sale; GSK penalized in South Korea for administrative...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Pfizer is considering selling a facility it bought from Abzena in...
View ArticleNovartis sues FDA over approval of Entresto generic, following rejection of...
Novartis is going after the FDA over the agency’s decision to approve a generic version of the cardiovascular drug Entresto earlier this year. The Swiss drugmaker sued the government after the FDA in...
View ArticleClik here to view.
RSV market pressure leads to slower launch for Moderna's vaccine
The RSV market is turning out to be tougher than Moderna hoped. Jamey Mock The company’s mResvia is the third RSV vaccine to enter a market dominated by GSK’s Arexvy and Pfizer’s Abrysvo. That pressure...
View ArticleDespite recent trial success, uniQure plans to cut 65% of staff
Less than a month after promising data sent uniQure’s shares soaring, the company is disclosing significant layoffs to 65% of the company. The new wave of cuts disclosed in the biotech’s second-quarter...
View Article